Premium
Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type‐5 inhibitor
Author(s) -
YU JAE YOUNG,
KANG KYUNG KOO,
YOO MOOHI,
KWON JONG WON
Publication year - 2005
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2005.01039.x
Subject(s) - medicine , erectile dysfunction , stimulation , cgmp specific phosphodiesterase type 5 , phosphodiesterase inhibitor , blood pressure , intracavernous injection , anesthesia , endocrinology
Aim: This study was conducted to investigate the effect of DA‐8159, a new phosphodiesterase type‐5 (PDE5) inhibitor, on electrostimulation‐induced penile erection in rats. Methods: Intracavernous pressure (ICP) and arterial blood pressure (BP) were simultaneously recorded through electric pelvic‐ganglion stimulation (2–10 Hz) after the oral administration of DA‐8159 (3 or 10 mg/kg) in normal and streptozotocin‐induced diabetic rats. Statistical analysis was performed on the maximal intracavernous pressure (ICP), detumescence time, maximal intracavernous pressure/blood pressure (ICP/BP) ratio, and the area under the curve (AUC) of the ICP/BP ratio. Results: In normal and diabetic rats, electrical stimulation of the pelvic ganglion induced a frequency‐ and dose‐dependent increase in the intracavernous pressure. The ICP/BP ratio and the corresponding AUC values were also significantly and dose‐dependently increased after DA‐8159 administration. In addition, the detumescence time significantly increased after DA‐8159 administration compared to that of the controls. Conclusions: These results show that the DA‐8159 significantly increased the intracavernous pressure response and prolonged the decay period induced by electrical stimulation of the pelvic ganglion, and suggest that DA‐8159 might be a potential therapeutic agent for the treatment of erectile dysfunction.